Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

88 results about "Agonist peptide" patented technology

Glucagon-like peptide-1 receptor agonists, also known as GLP-1 receptor agonists or incretin mimetics, are agonists of the GLP-1 receptor. This class of medications is used for the treatment of type 2 diabetes.

Stabilized GLP-1 peptides and dual agonist peptides against GLP-1r and GIPR and methods of use thereof

PCT designated stage expiredWO2025024788A1BacteriaMetabolism disorderAgonist peptideAnti proteases
The present application provides protease-resistant Glucagon-Like Peptide 1 (eGLP-1) peptides, and also provides protease-resistant dual agonist peptides against GLP-1R and GIPR, methods of making such peptides, as well as compositions comprising protease-resistant peptides and methods of treatment utilizing such peptides.
Owner:BIOMEDIT LLC

Albumin Bound Macromolecule Tri-Agonist Activating GLP-1 / GIP / Glucagon Receptors

A pharmaceutical composition comprises a GPCR agonist fusion protein in which a GPCR agonist peptide is covalently coupled to albumin via a linker in a manner that is resistant to a retro-Michael addition. Advantageously, compositions presented herein avoid decoupling of the agonist form the albumin while retaining the agonist in a steric relationship to the albumin that allows for effective binding and activation of the GPCR while also enabling gp60-mediated transcytosis and FcRn-mediated albumin recycling. These properties enable ultra-low dosages for the GPCR agonist fusion protein to give a therapeutic effect while substantially reducing or even entirely avoiding adverse effects otherwise commonly associated with unbound agonists. Such retro-Michael resistant composition is generally achieved by conformational modification of the albumin, resulting in stereoselective coupling of the linker to the albumin.
Owner:ALBUNEXT LLC

Therapeutic regimens and methods for lowering blood glucose and / or body weight using GLP-1R and GCGR balanced agonists

This disclosure relates to the once weekly dosing regimen of a dual GLP-1R and GCGR agonist, formulations, and methods of using the same for treatment of chronic weight management, obesity and / or blood glucose control, including but not limited to dual agonist peptide product of SEQ ID NO. 1.
Owner:SPITFIRE PHARMA LLC

Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and GLP-1 receptor agonist peptides

Described herein is a method of treating a disease or condition, for example, obesity, weight gain, or diabetes, comprising administering to a subject in need thereof a glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist and a glucagon-like peptide 1 receptor (GLP-1R) agonist. Further described herein are pharmaceutical compositions comprising a GIPR antagonist and a GLP-1R agonist, which may be useful in the treatment of a disease or condition, for example, obesity, weight gain, or diabetes.
Owner:PFIZER INC

Albumin bound macromolecule tri-agonist activating GLP-1 / GIP / glucagon receptors

A pharmaceutical composition comprises a GPCR agonist fusion protein in which a GPCR agonist peptide is covalently coupled to albumin via a linker in a manner that is resistant to a retro-Michael addition. Advantageously, compositions presented herein avoid decoupling of the agonist form the albumin while retaining the agonist in a steric relationship to the albumin that allows for effective binding and activation of the GPCR while also enabling gp60-mediated transcytosis and FcRn-mediated albumin recycling. These properties enable ultra-low dosages for the GPCR agonist fusion protein to give a therapeutic effect while substantially reducing or even entirely avoiding adverse effects otherwise commonly associated with unbound agonists. Such retro-Michael resistant composition is generally achieved by conformational modification of the albumin, resulting in stereoselective coupling of the linker to the albumin.
Owner:ALBUNEXT LLC

Albumin Bound Macromolecule Tri-Agonist Activating GLP 1 / GIP / Glucagon Receptors And Methods Therefor

A pharmaceutical composition comprises a GPCR agonist fusion protein in which a GPCR agonist peptide is covalently coupled to albumin via a linker in a manner that is resistant to a retro-Michael addition. Advantageously, compositions presented herein avoid decoupling of the agonist form the albumin while retaining the agonist in a steric relationship to the albumin that allows for effective binding and activation of the GPCR while also enabling gp60-mediated transcytosis and FcRn-mediated albumin recycling. These properties enable ultra-low dosages for the GPCR agonist fusion protein to give a therapeutic effect while substantially reducing or even entirely avoiding adverse effects otherwise commonly associated with unbound agonists. Moreover, these properties also enable transport of the GPCR agonist fusion protein across the blood brain barrier and therefore allow treatment of neural disorders.
Owner:ALBUNEXT LLC

Macromolecular triple agonists that activate albumin binding of GLP-1 / GIP / glucagon receptor

A pharmaceutical composition comprises a GPCR agonist fusion protein wherein the GPCR agonist peptide is covalently conjugated to an albumin via a linker in a manner that is resistant to a reverse Michael addition. Advantageously, the compositions presented herein avoid uncoupling of the agonist to the albumin while maintaining the agonist and the albumin in a spatial relationship that allows efficient binding and activation of the GPCR while also enabling gp60-mediated endocytosis transport and FcRn-mediated albumin recirculation. These characteristics enable ultra-low doses of GPCR agonist fusion proteins to produce therapeutic effects while significantly reducing or even completely avoiding side effects that would otherwise be typically associated with unbound agonists. Such reverse Michael resistant compositions are typically achieved by conformationally modifying an albumin, resulting in a stereoselective coupling of a linker to the albumin.
Owner:ALBUNEXT LLC

Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and GLP-1 receptor agonist peptides

Described herein is a method of treating a disease or condition, for example, obesity, weight gain, or diabetes, comprising administering to a subject in need thereof a glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist and a glucagon-like peptide 1 receptor (GLP-1R) agonist. Further described herein are pharmaceutical compositions comprising a GIPR antagonist and a GLP-1R agonist, which may be useful in the treatment of a disease or condition, for example, obesity, weight gain, or diabetes.
Owner:PFIZER INC

CircRNA nano delivery system capable of reversing nucleus pulposus progenitor cell senescence and preparation method and application of circRNA nano delivery system

The invention discloses a circRNA nano delivery system capable of reversing nucleus pulposus progenitor cell senescence and a preparation method and application of the circRNA nano delivery system. The circRNA nano delivery system comprises: a) Klotho circRNA, and b) a liposome, and the liposome comprises a vascular peptide vasculotide, an ionizable lipid molecule, a phospholipid, a PEG lipid, and a steroid. The invention also provides application of the circRNA nano delivery system capable of reversing nucleus pulposus progenitor cell senescence in preparation of drugs for treating intervertebral disc degeneration. The invention provides liposome particles (Vas-Klotho-LNP) which have targeted NPPCs and wrap circRNA, Klotho circRNA is efficiently introduced into the NPPCs through Tie2 agonist peptide, so that rejuvenation of the NPPCs is promoted, ECM synthesis is promoted, and regeneration and repair of intervertebral discs are synergistically promoted in vivo and in vitro.
Owner:SHANDONG UNIV QILU HOSPITAL

Albumin bound macromolecule tri-agonist activating GLP 1 / GIP / glucagon receptors and methods therefor

A pharmaceutical composition comprises a GPCR agonist fusion protein in which a GPCR agonist peptide is covalently coupled to albumin via a linker in a manner that is resistant to a retro-Michael addition. Advantageously, compositions presented herein avoid decoupling of the agonist form the albumin while retaining the agonist in a steric relationship to the albumin that allows for effective binding and activation of the GPCR while also enabling gp60-mediated transcytosis and FcRn-mediated albumin recycling. These properties enable ultra-low dosages for the GPCR agonist fusion protein to give a therapeutic effect while substantially reducing or even entirely avoiding adverse effects otherwise commonly associated with unbound agonists. Moreover, these properties also enable transport of the GPCR agonist fusion protein across the blood brain barrier and therefore allow treatment of neural disorders.
Owner:ALBUNEXT LLC

Anti-gastric inhibitory polypeptide receptor (GIPR) antibodies and antibody conjugates for the treatment of metabolic disorders

Disclosed herein are antibodies, agonist peptides, and dual agonist peptides. Further disclosed herein are antibody conjugates comprising the antibodies, agonist peptides, and / or dual agonist peptides disclosed herein. In some embodiments, the antibodies or antibody conjugates of the invention may be used to treat metabolic diseases.
Owner:PFIZER INC

MC4r agonist peptides

Provided herein are melanocortin 4 receptor (MC4R) agonist peptides and methods of use thereof for the treatment and / or prevention of eating disorders (e.g., overeating), metabolic disorders (e.g., disorders resulting in positive energy imbalance), emotional / mental disorders, and / or dietary or syndromic obesity. In particular, provided herein are MC4R agonist peptides that exhibit enhanced selectivity for MC4R over other melanocortin receptors (e.g., MC1R, MC2R, MC3R, MC5R) and / or are MC3R antagonists or partial agonists. The peptides herein may exhibit enhanced in vitro potency, in vivo efficacy, pharmacokinetic properties, and / or stability compared to other known melanocortin receptor binding peptides.
Owner:COURAGE THERAPEUTICS INC +1

Formulations of guanylate cyclse c agonists and methods of use

The invention provides low-dose formulations of guanylate cyclase-C (“GCC”) agonist peptides and methods for their use. The formulations of the invention can be administered either alone or in combination with one or more additional therapeutic agents, preferably an inhibitor of cGMP-dependent phosphodiesterase or a laxative.
Owner:BAUSCH HEALTH IRELAND LTD

Albumin bound macromolecule TRI-agonist activating GLP-1 / GIP / glucagon receptors

A pharmaceutical composition comprises a GPCR agonist fusion protein in which a GPCR agonist peptide is covalently coupled to albumin via a linker in a manner that is resistant to a retro-Michael addition. Advantageously, compositions presented herein avoid decoupling of the agonist form the albumin while retaining the agonist in a steric relationship to the albumin that allows for effective binding and activation of the GPCR while also enabling gp60-mediated transcytosis and FcRn-mediated albumin recycling. These properties enable ultra-low dosages for the GPCR agonist fusion protein to give a therapeutic effect while substantially reducing or even entirely avoiding adverse effects otherwise commonly associated with unbound agonists. Such retro-Michael resistant composition is generally achieved by conformational modification of the albumin, resulting in stereoselective coupling of the linker to the albumin.
Owner:ALBUNEXT LLC

Compounds for treating metabolic disorders

Provided are novel compounds for GIPR, GLP-1R and GCGR. Specifically, provided are GLP-1R / GIPR / GCGR triagonists peptides, and conjugates comprising an Fc fragment and GLP-1R / GIPR / GCGR triagonists peptides. Pharmaceutical compositions comprising these compounds,as well as uses thereof in treating metabolic conditions and disorders, such as diabetes mellitus, type 2 diabetes, obesity, metabolic dysfunction-associated fatty liver disease (MAFLD), non-alcoholic fatty liver disease (NAFLD), metabolic dysfunction-associated steatohepatitis (MASH), and non-alcoholic steatohepatitis (NASH) are also provided.
Owner:INNOVENT BIOLOGICS (SUZHOU) CO LTD +1

GLP-1r agonistic peptides with reduced activity

To provide GLP-1R agonistic peptides with reduced GLP-1R agonistic activity, fusion molecules comprising the same and pharmaceutical compositions.SOLUTION: The invention provides a GLP-1R agonistic peptide whose GLP-1R agonistic activity is about 9- to about 531-fold reduced as compared to the GLP-1R agonistic activity of native GLP-1 of a specific sequence. The invention also provides a nucleic acid molecule encoding GLP-1R agonistic peptide with reduced GLP-1R agonistic activity, a pharmaceutical composition comprising a GLP-1R agonistic peptide with reduced GLP-1R agonistic activity and combinations thereof. The pharmaceutical composition is for treating obesity, overweight, metabolic syndrome, diabetes, diabetic retinopathy, hyperglycemia, dyslipidemia, non-alcoholic steatohepatitis (NASH) and / or atherosclerosis.SELECTED DRAWING: None
Owner:SANOFI SA(FR)

Combination therapy

The present invention relates to methods of treatment using acylated compounds and peptide hormones having dual agonist activity for the GLP-1 (glucagon-like peptide 1) and GLP-2 5 (glucagon-like peptide 2) receptors. In particular, the present invention relates to the administration of a dual GLP-1 / GLP-2 agonist peptide and amylin for modulating body weight and preventing or treating obesity and related conditions.
Owner:ZEALAND PHARMA AS

Improved GIP receptor agonist peptide compounds and uses thereof

The present disclosure provides GIP receptor agonist peptide compounds suitable for once per day dosing (QD), said peptide compounds having an activating action on GIP receptors and use of the GIP receptor agonist peptide as a medicament for the treatment and / or prevention of emesis, or a symptom or condition associated with emesis while having an improved profile.
Owner:TAKEDA PHARMA CO LTD

Corticotropin releasing factor receptor 2 (CRFR2) agonists

This disclosure provides corticotropin releasing factor receptor 2 (CRFR2) agonist peptides, pharmaceutical compositions comprising such peptides, and methods of using such peptides to treat and / or prevent, for example, cardiovascular diseases, obesity, diabetes, sarcopenia, cachexia, kidney disease, heart failure and pulmonary hypertension.
Owner:NEUROCRINE BIOSCIENCES INC

Stable GLP-1 peptides and dual agonist peptides against GLP-1r and GIPR and methods of use thereof

The present application provides protease resistant glucagon-like peptide 1 (eGLP-1) peptides, as well as protease resistant dual agonist peptides directed against GLP-1R and GIPR, methods of making these peptides, as well as compositions comprising the protease resistant peptides and methods of treatment utilizing these peptides.
Owner:BIOEDIT CO LTD

GLP1-r / GIPR dual peptide agonists and use thereof

PCT designated stage expiredWO2025087344A1BacteriaMetabolism disorderDiseaseAgonist peptide
Provided is dual target agonist peptides, and more specifically to a series of dual target agonists that can simultaneously activate the human Glucagon like peptide-1 (GLP-1) receptor and the human glucose dependent insulinotropic polypeptide (GIP) receptor, as well as its pharmaceutical salts and pharmaceutical compositions. The peptides have dual agonist effect and can be used for the treatment of diabetes, obesity and other related diseases.
Owner:BETA PHARMA INC

Pharmaceutical formulation of glucagon-like peptide-1 receptor agonist peptides suitable for sublingual administration

The present disclosure relates to a pharmaceutical formulation suitable for sublingual administration for use in the treatment of obesity, type II diabetes, or related diseases. The pharmaceutical formula comprises 5 to 10 milligrams of glucagon-like peptide-1 receptor agonist peptide (GLP-1 RA-P) which is dissolved in 1.5 to 2.0 milliliters of a buffer solution, and the pH (Potential of Hydrogen) value of the pharmaceutical formula is 5.5 to 7.5. The disclosure also discloses a method for treating obesity, type II diabetes, or related diseases. The method comprises administering the pharmaceutical formulation of the present disclosure to a subject in a sublingual administration, and allowing the pharmaceutical formulation to be continuously located sublingually of the subject for 5-10 minutes, where the pharmaceutical formulation has a bioavailability for GLP-1 RA-P of 2-10% compared to the administration to the subject through subcutaneous injection.
Owner:IMMUNWORK INC

Hydrochloride salts of C5a receptor agonist peptides

Hydrochloride salt forms of synthetic C-terminal peptide analogs of C5a, which are response selective agonists of C5aR-bearing antigen presenting cells. Methods of inducing an immune response in a subject by administering such peptide analogs alone or in combination with other active agents are also disclosed.
Owner:SAN DIEGO STATE UNIV RES FOUND +1

Gip / glpi agonist compositions

The present invention relates to GIP / GLP1 agonist compositions. The present invention is a GIP / GLP1 co-agonist peptide pharmaceutical composition for subcutaneous injection. The composition comprises tirzepatide, NaCl, and disodium hydrogen phosphate. The composition provides commercially acceptable shelf-life stability, use-life stability, and an acceptable patient injection site experience. An alternative composition comprises tirzepatide, propylene glycol, and disodium hydrogen phosphate, which also provides acceptable shelf-life stability.
Owner:ELI LILLY & CO

Dual amylin calcitonin receptor agonists

PCT designated stage expiredWO2025147628A3Peptide/protein ingredientsCalcitoninsCalcitonin receptorPharmaceutical drug
Peptides that exhibit amylin and calcitonin receptor agonist activity (DACRAs) are provided as well as prodrug derivatives thereof. Analogs having enhanced agonist selectivity for the calcitonin receptor relative to amylin are also provided as well as conjugates of the DACRA peptides with incretin peptides. Pharmaceutical compositions comprising such peptide analogs and therapeutic methods of using such peptide analogs are also provided.
Owner:INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORP

Use of lauryl gallate (LG) as a hemostatic agent

The food additive lauryl gallate (LG, E312) is a molecule with antioxidant and hydrophobic properties which has also been shown to exert antibacterial, antiviral and anti-tumoral effects. Here, the inventors show that LG at a low concentration has the ability to spontaneously induce washed human platelet shape change, filopodia emission, granule secretion, phosphatidylserine expression and aggregation. LG was able to activate intracellular signaling pathways including Akt, p38MAP-kinase and calcium response and to trigger activation of the αIIbβ3 integrin. LG also significantly potentiated platelet aggregation induced by low doses of collagen or thrombin receptor agonist peptide. Consistent with this, low doses of LG added to human blood promoted a strong platelet thrombotic response under arterial flow on a collagen matrix. As shown by electron microscopy, at a high concentration, LG induced a dramatic platelet membrane modification associated with calcium influx and a slow platelet aggregation response. Finally, a local flash-application of LG efficiently decreased the tail bleeding in rats suggesting that this compound has the potential to act as a hemostatic. Overall, the results indicate that the food additive LG, possibly through its capacity to modify membrane lateral organization, has pro-aggregant and antihemorrhagic properties.
Owner:CENT DE BIOTECH DE SFAX - CBS +2

Compounds as TGF-beta receptor agonist peptides and uses thereof

The invention belongs to the field of polypeptide medicines, and particularly relates to a compound serving as a TGF-beta receptor agonist peptide and application of the compound. The amino acid sequence of the polypeptide is as shown in SEQ ID No. 1. The polypeptide disclosed by the invention has a remarkable agonistic effect on a TGF-beta receptor, and can be applied to preparation of medicines for preventing and / or treating diseases related to TGF-beta, in particular to prevention of alopecia and / or promotion of hair growth.
Owner:HUNAN ZONSEN PEPLIB BIOTECH CO LTD

GIP / GLP1 agonist compositions

The present invention relates to a GIP / GLP1 agonist composition. The present invention relates to a GIP / GLP1 co-agonist peptide pharmaceutical composition for subcutaneous injection. The composition is prepared from tilpotide, NaCl and disodium hydrogen phosphate. The compositions provide commercially acceptable shelf-life stability, shelf-life stability, and are related to acceptable patient injection site experiences. Alternatively, the composition comprises tirpotide, propylene glycol, and disodium hydrogen phosphate, which also provides acceptable shelf life stability.
Owner:ELI LILLY & CO

Antibody-fusion protein conjugates

PendingCO20260002199A2DiseaseDiabetes mellitus
The present invention relates to immunoglobulins, such as immunoconjugates, comprising an ActRII receptor antibody and a GLP-1 agonist molecule, such as a GLP-1 agonist peptide. Such constructs are useful in the treatment of numerous diseases and disorders, including metabolic disorders such as obesity, diabetes, and others.
Owner:SIXPEAKS BIO AG